BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

BriaCell (BCTX) Therapeutics announces that the independent Data Safety Monitoring Board, DSMB, has issued its fifth consecutive positive recommendation following review of safety data from BriaCell’s Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor, CPI, in patients with metastatic breast cancer. Following its review, the DSMB raised no safety concerns and recommended that the study continue without modifications. DSMB meetings occur quarterly in accordance with the study protocol. BriaCell’s ongoing pivotal Phase 3 study is being conducted under Fast Track designation granted by the US Food and Drug Administration, reflecting the significant unmet medical need in metastatic breast cancer.